Explore

Rapid Read Rapid Read
New Medicaid Rules May Disqualify Sick Recipients from Coverage

New Medicaid Rules May Disqualify Sick Recipients from Coverage

The Trump administration has introduced new Medicaid eligibility rules requiring recipients with serious health conditions, such as cancer, to prove their inability to work to maintain coverage. These rules, set to take effect next year, aim to tighten eligibility criteria for Medicaid, potentially affecting many who rely on the program for healthcare. Colorado Medicaid director Adela Flores-Brennan has outlined the state's preparations to address these changes. The rules have sparked concern among healthcare advocates who argue that they could lead to vulnerable individuals losing essential healthcare coverage.
Rapid Read Rapid Read
UK Pharmacists Enhance Cardiovascular Care Through Innovative Practices

UK Pharmacists Enhance Cardiovascular Care Through Innovative Practices

The UK Clinical Pharmacy Association (UKCPA) is advancing cardiovascular care by integrating pharmacists into patient care teams across the UK. Pharmacists are playing a crucial role in optimizing medication, improving patient safety, and contributing to education and research. The UKCPA's Cardiovascular Disease Committee exemplifies this by providing specialist education and setting practice standards. Pharmacists are involved in various innovative roles, such as running post-myocardial infarction clinics, optimizing lipid therapies, and contributing to national guidelines. These efforts are part of a broader strategy to reduce cardiovascular risk and improve patient outcomes.
Trendline Trendline
Novo Nordisk and Eli Lilly Compete for GLP-1 Pill Market Amid Medicare Coverage Expansion

Novo Nordisk and Eli Lilly Compete for GLP-1 Pill Market Amid Medicare Coverage Expansion

Novo Nordisk and Eli Lilly Compete for GLP-1 Pill Market Amid Medicare Coverage Expansion
TheStreet TheStreet
Mark Cuban goes in hard on the American healthcare system

Mark Cuban goes in hard on the American healthcare system

Mark Cuban has spent years criticizing American healthcare from the outside. Then he built a drug company, Cost Plus Drugs, to prove his point. Then he wrote a blog post that went viral among healthcare industry insiders for saying out loud what most people in the system already know but rarely say ...
Reuters Reuters
UK reviewing Palantir's NHS contract amid pressure to use break clause

UK reviewing Palantir's NHS contract amid pressure to use break clause

LONDON, June 9 (Reuters) - Britain is conducting a full review of its National Health Service contract with U.S. data analytics firm Palantir, amid growing political pressure for the government to use a break clause at the end of the initial term in early 2027.
Rapid Read Rapid Read
Federal Reforms to No Surprises Act Aim to Ease Dispute Resolution for Laboratories

Federal Reforms to No Surprises Act Aim to Ease Dispute Resolution for Laboratories

The No Surprises Act, enacted by Congress to protect patients from unexpected out-of-network medical bills, has undergone significant reforms to address the complexities and inefficiencies in its dispute resolution process. Since its implementation in 2022, the Federal Independent Dispute Resolution (IDR) process has been overwhelmed with over five million disputes, far exceeding initial projections. This has led to backlogs, increased costs, and frustration among healthcare providers and payors. Recent reforms finalized by the Departments of Health and Human Services, Labor, Treasury, and the Office of Personnel Management aim to streamline the process, particularly benefiting laboratories and diagnostic providers. Key changes include reducing the administrative fee for disputes from $115 to $15, expanding batching flexibility for similar claims, and requiring standardized communication codes for payment decisions.
Rapid Read Rapid Read
CMS Warns Over 500 Hospitals for Price Transparency Failures, Potential Penalties Loom

CMS Warns Over 500 Hospitals for Price Transparency Failures, Potential Penalties Loom

The Centers for Medicare and Medicaid Services (CMS) has issued warnings to over 500 hospitals across the United States for failing to meet federal price transparency requirements. These hospitals have received either a 90-day warning notice or a Corrective Action Plan (CAP) request, which requires them to address compliance deficiencies within 45 days. If hospitals fail to comply, they face civil monetary penalties that can reach up to $5,500 per day, potentially exceeding $2 million annually. The enforcement of these requirements began during the Trump administration and continued under President Biden, with ongoing interest from Republican lawmakers to address healthcare pricing frustrations. Despite the availability of pricing data, experts note that it has not been widely utilized at the patient level, though it has been beneficial for payers and providers during negotiations.
AP News AP News
Trump administration warns more than 500 hospitals to provide more price information or face fines

Trump administration warns more than 500 hospitals to provide more price information or face fines

The Trump administration has warned more than 500 hospitals that they are failing to provide the public with enough information about prices
Rapid Read Rapid Read
FDA Introduces New Pathways for Rare Disease Therapies Amid Unanswered Questions

FDA Introduces New Pathways for Rare Disease Therapies Amid Unanswered Questions

The FDA has introduced new pathways, including the plausible mechanism pathway and rare disease evidence principles (RDEP), to accelerate the development of therapies for rare diseases. These initiatives aim to provide faster routes to market for investigational therapies, particularly those targeting rare conditions with small patient populations. However, the specifics of these pathways remain unclear, leaving industry experts with questions about their implementation and impact. The plausible mechanism pathway, for instance, is designed to allow approval based on evidence of biological target engagement and clinical improvement, but its commercial implications and regulatory exclusivities are still uncertain.
Trendline Trendline
Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment
Trendline Trendline
Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Treatment Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Treatment Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Treatment Candidate AMB-702
Rapid Read Rapid Read
Finerenone Drug Shows Promise for Broader Kidney Disease Treatment

Finerenone Drug Shows Promise for Broader Kidney Disease Treatment

Recent international studies have revealed that the kidney disease drug finerenone may benefit a wider range of patients than previously thought. Traditionally used to treat chronic kidney disease (CKD) associated with type 2 diabetes, finerenone has shown potential in helping patients with non-diabetic CKD and certain glomerular diseases. The findings, presented at the European Renal Association Congress and published in leading medical journals, indicate that finerenone can slow kidney function decline, reduce cardiovascular risks, and improve survival rates. The studies, including the FIND-CKD trial, demonstrated that finerenone reduced the risk of kidney failure, CKD progression, heart failure, and cardiovascular death by significant margins.